
What happened
CytoSorbents Corporation (NASDAQ: CTSO) agreed to a $6.25 million financing that would pay down its Avenue Capital Group loan with cash and stock. The planned repayments would cut principal from $17.5 million before the Nov. 19 agreement to $12.25 million, a 30.0% drop, OptimistFi calculates.
Shareholders face dilution in exchange for lower borrowing costs. The registered direct offering of shares and pre-funded warrants would raise about $4 million before expenses and about $3.5 million after them. Existing shareholders, management and directors subscribed for about three-quarters of the offering.
Key numbers
| Metric | Latest | Change | Source |
|---|---|---|---|
| Announced common stock financing, including the debt exchange | $6.25 million | CytoSorbents press release | |
| Expected gross cash proceeds | About $4 million | CytoSorbents press release | |
| Estimated net offering proceeds | About $3.5 million | SEC 8-K | |
| Expected reduction in loan principal | $5.25 million | CytoSorbents press release | |
| Expected remaining loan principal | $12.25 million | CytoSorbents press release | |
| Expected interest savings over 12 months | About $700,000 | CytoSorbents press release |
Read more: CytoSorbents (CTSO) company research
Why it matters
CytoSorbents expects to save about $700,000 in interest over 12 months. The amendment moves the due date from July 1, 2027, to July 1, 2028, and extends interest-only payments through March 31, 2028.
The amendment also gives CytoSorbents more room under its cash-burn covenant. The threshold rises to $3.2 million for testing periods through Dec. 31 and is $2 million otherwise.
Further debt relief could dilute shareholders again. Lenders can convert part of the principal into stock at $6.92 a share. They can convert another portion at $8.65 a share starting Jan. 1, 2028, or sooner if the FDA grants marketing approval for DrugSorb-ATR.
In OptimistFi's view, the lower debt load helps, but CytoSorbents still needs wider use of its blood purification devices in intensive care and cardiac surgery to outpace cash burn.
Stock perps: every US stock that trades as a perpetual future, by leverage, live
What's next
The offering is expected to close on or about Nov. 20 if standard closing conditions are met. The principal will fall only once CytoSorbents makes the cash repayment and completes the stock exchange. Both are expected around the same time as the offering close.
More from OptimistFi
From OptimistFi Perps
- Prop firms that fund crypto and stock perps traders: rules, prices and payouts
- Top perps movers today: stocks, commodities, FX and indices
- Open interest live: crypto and stock perps by exchange
- All perp markets: price, open interest and funding by venue
- Futures calculator: liquidation price, PnL and fees by exchange
- Perp funding rates live: what longs and shorts pay on every venue
Sources
- CytoSorbents press release — Nov. 20, 2026 announcement of the common stock financing and the loan restructuring with Avenue Capital Group.
- SEC 8-K — Reports the Nov. 19, 2026 agreements, estimated net proceeds and revised loan terms.
Explore OptimistFi research on CytoSorbents Corporation: https://optimistfi.com/stocks/CTSO
Browse CytoSorbents Corporation company coverage and explore the OptimistFi Thesis-Break Engine.
Browse every company OptimistFi covers at optimistfi.com/stocks, or read the latest evidence-first research.
Find available research on the CytoSorbents Corporation company page.
Originally published on OptimistFi, evidence-first equity research. More at optimistfi.com.
